CONTACT
+91 80 2808 2808
info@biocon.com
Biocon  /  Businesses  /  Biosimilars  /  Wide Global Footprint

BIOCON BIOSIMILARS

Wide Global Footprint

null

We are among the select few globally to have co-developed five biosimilars, bTrastuzumab, bBevacizumab, bPegfilgrastim, bGlargine and bAspart, which have received approvals in key advanced markets and three of these are also commercialized in these markets through our partner Viatris. We can effectively manage the risks entailed in taking advanced therapies from ‘bench to bedside’, even in the most stringently regulated markets. We are also among the few to have successfully commercialized five biosimilars, bTrastuzumab bBevacizumab, bPegfilgrastim, bGlargine, rh-Insulin, in many emerging markets though our strong network of partners.

As a leading global insulins player, Biocon Biologics is already benefiting people with diabetes in many emerging and developed markets through improved access to its more affordable recombinant human Insulin and insulin analogs. Biocon Biologics has supplied ~2.75 billion doses of rhInsulin globally since its launch in India in 2004.

Given our extensive experience in providing affordable insulins globally, we aspire to drive policy changes to increase access and transform patients’ lives. To translate intention into action, we rolled out our ‘Mission 10 cents’ program in Philippines and Tanzania in FY21. Under this program, we offer governments in low- and middle-income countries (LMICs) our rh-Insulin for less than 10 U.S. cents a day. Through our local partners, we engaged in diabetes awareness campaigns to promote early diagnosis and better diabetes management.

To contribute to a stronger global voice for diabetes patients globally, we entered a partnership with the International Diabetes Federation (IDF) in 2021, coinciding with the start of the centenary celebrations of the discovery of insulin.

With bTrastuzumab, bPegfilgrastim and bBevacizumab, we are positioned uniquely to provide a broad range of treatment options for cancer patients. We are working with our partners and healthcare systems across the globe to reduce costs, improve access to biologics therapy and advance the quality of care. In the oncology space, Biocon Biologics has signed an agreement with the Clinton Health Access Initiative (CHAI) to expand access to lifesaving cancer biosimilars in over 30 countries in Africa and Asia as a part of the Cancer Access Partnership (CAP). The partnership is a significant step in delivering advanced cancer therapies to patients who need them the most and ensuring equitable access to high-quality biosimilars in low- and middle-income countries (LMICs).

null

null

CORPORATE GOVERNANCE
KEY THERAPEUTIC AREAS
RESEARCH SERVICES
OUR CULTURE
RESPONSIBILITY
Share
Previous Next
Close
Test Caption
Test Description goes like this